



Third Quarter 2021 Financial Results and Business Update Conference Call

Karim Mikhail
President & CEO

Michael Kalb
CFO

November 3, 2021




Forward-Looking Statements

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA[®] (VAZKEPA in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, generic product launch, intellectual property, cash flow, research and development, and other statements that are forward-looking in nature and depend upon or refer to future events or conditions, including financial guidance and milestones. These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the “Risk Factors” section in Amarin’s most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

This presentation is intended for communication with investors and not for drug promotion.

AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.


Amarin Future Growth Strategy




Third Quarter Financial Highlights

- Total revenue of \$142.0 million, compared with \$156.5 million in Q3'20
- U.S. VASCEPA franchise is profitable
- \$517.9 million in cash and investments and no debt
- Strong balance sheet to support growth and expansion plans

Q3 Total and Net Product Revenue (\$M)




IPE Market Erosion vs Statin Market Erosion



ZS AccessMonitor™ reveals that 29% of physicians were accessible in the second half of 2020, a significant recovery from a mere 7% accessible physicians in first half of 2020


Accessible Physicians Trend*



*HCPs with AM No-See Rating of 8 to 10 are considered to be accessible
*Based on 240k to 350k Physicians who have been evaluated in different semesters

Reproduced with permission from
ZS AccessMonitor™

Amarin Go-to-Market Strategy to Drive Growth in the US



Expanding Healthcare Provider Engagement:

3-4X amplification of physicians reach through digital channels

Sales force optimization to focus on the most productive and accessible territories

Managed Care Access Enhancement:


Drive incremental volume growth through further removing barriers to VASCEPA Rx to ensure that patients in need of CV risk reduction receive proper therapy

Optimizing VASCEPA Prescriptions for CV Risk Reduction:

Address gaps in Prescribing Ecosystem to Reduce Inappropriate Generic Substitution

Evaluating various innovative solutions designed to better manage IPE Rx for CVRR

Iterative Process with Measurable Results



Launched VAZKEPA in Germany

Relentless focus on education, awareness & access



3.9M

deaths per year in Europe
due to CVD¹

~€210B

annual CVD costs to European Union²

10+

years of market exclusivity in Europe



VAZKEPA in Europe: *A Significant Market Opportunity*

- ✓ Filed market access dossiers in ten key EU countries ahead of YE schedule
- Multiple EU country launches expected in 2022
- Plans to file next wave of five market access dossiers in 2022
- Dynamic Go-to-Market strategy includes significant digital initiatives to efficiently enhance and expand customer engagement
- Customized, bespoke model easily adapted to the specificities of individual markets

1) European Heart Network. European Cardiovascular Disease Statistics 2017. <https://ehnheart.org/cvd-statistics/cvd-statistics-2017.html>. Accessed August 2021

2) European Heart Network. European Cardiovascular Disease Statistics 2017. <https://ehnheart.org/cvd-statistics/cvd-statistics-2017.html>. Accessed August 2021

International Growth Represents Potential \$1+ Billion Opportunity

Plans to Bring Unique Cardioprotective Benefits of VASCEPA/VAZKEPA to 20 Additional Markets

First Wave 2022

- Regulatory filings and approvals:
 - Australia
 - New Zealand
 - Israel
 - up to 3 others

Second Wave 2023

- Regulatory filings and approvals:
 - Up to 9 other countries

Third Wave 2024

- Regulatory filings and approvals:
 - Up to 5 other countries


Supported by REDUCE-IT Study and U.S. FDA and EMA Filings

Note: The company is pursuing expansion into these various additional markets and the status of regulatory and/or patent approval will vary between market to market.


- Ongoing systematic review of potential assets in cardiometabolic and obesity spaces
- Considering unique assets not only for large populations but also specialty and rare diseases with great unmet need
- Prioritizing two types of assets:
 - Near term commercial potential
 - Development stage with transformative potential

Diversification

Third Quarter Total and Net Product Revenue



Amarin: An Exciting Opportunity to Create Value



- Grow and defend VASCEPA despite generics' presence on the market for the VHTG indication
- Advance the Go-to-Market digital omnichannel model to drive greater awareness and demand



- Build awareness of VAZKEPA across EU as we prepare for strong sequenced launches in key markets throughout 2022
- Value based proposed list price of ~€200 or \$240 monthly



- Bring CV benefits of VASCEPA to at least 20 additional markets internationally
- Initiate the regulatory processes and obtain additional approvals in First Wave in 2022



- Seek partnerships and opportunities to leverage growing global commercial infrastructure and competent R&D team

Q&A

